



**Determinazione del Responsabile Ufficio Formazione n° 1447 del 23 AGO 2016**

**Oggetto: Aggiornamento senza oneri, Dirigente Medico, Dott. Loi Bruno.**

Pubblicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 23 AGO 2016 per 15 giorni consecutivi e posta a disposizione per la consultazione.

**Il Responsabile Ufficio Formazione**

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 16122 del 22.07.2016 con la quale la Ditta Edwards si è resa disponibile ad invitare un Dirigente Medico al Congresso: "PCR London Valves" che si terrà a Londra dal 18 settembre al 20 settembre 2016;
- Considerato** che il Direttore del Dipartimento Cardio Toraco Vascolare ha autorizzato a partecipare al suddetto Congresso il Dott. Loi Bruno;
- Atteso** che il Responsabile dell'Ufficio Formazione ha espresso parere favorevole in merito;
- Ritenuto** di dover autorizzare la partecipazione del Dott. Loi Bruno al Congresso: "PCR London Valves" che si terrà a Londra dal 18 settembre al 20 settembre 2016; di dover prendere atto che le spese di iscrizione, pernottamento, vitto e viaggio saranno totalmente a carico della Ditta Edwards;

**DETERMINA**

Per i motivi esposti in premessa:

1. Autorizzare la partecipazione del Dott. Loi Bruno al Congresso: "PCR London VALVES" che si terrà a Londra dal 18 settembre al 20 settembre 2016;
2. Dare atto che le spese di iscrizione, pernottamento, vitto e viaggio saranno totalmente a carico della Ditta Edwards;
3. Trasmettere la presente determinazione al Direttore della S.C. del Personale per gli adempimenti normativi di competenza.

Il Responsabile dell'Ufficio Formazione  
Dott. Andrea Corrias

Rapp invio fax


16-AGO-2016 11:08 MAR


Numero fax : 070539752  
Nome : UFF. FORMAZIONE

Nome/Numero : 00256806592  
Pag. : 1  
Ora iniz. : 16-AGO-2016 11:06 MAR  
Tempo trascorso : 01'44"  
Modalita' : STD ECM  
Risultati : [O.K.]

21. Lug. 2016 14:02 EDWARDS 0256806592 N. 2492 P. 1

**AO BROTZU**  
 PG/2016/ 0016122 del 22/07/2016 ore 08,17  
 MESSA : EDWARDS LIFE SCIENCES ITALIA SPA  
 Anagrafica : DIREZIONE SANITARIA



  
**Edwards**

Spettabile  
 Azienda Ospedaliera G. Brotzu  
 Piazza Alessandro Ricchi,  
 1, 09134 Cagliari  
 c.a.: Direzione Sanitaria  
 p.c. Primario del reparto di Cardiocirurgia

Milano, 2-1 LUG 2016

**AZIENDA OSPEDALIERA G. BROTZU**  
**UFFICIO FORMAZIONE**  
*F. M. S.*

OGGETTO: PCR London Valves 18 - 20 settembre 2016 (Londra)

La nostra Società parteciperà all'iniziativa in oggetto, fermo restando il rispetto della normativa del Ministero della Sanità in merito ai fini autorizzativi e procedurali, siamo lieti di invitare: n° 1 cardiocirurgo e n° 2 cardiologi interventisti che il Primario del Reparto vorrà segnalarci (dei quali la Vs. Amministrazione in piena e totale autonomia ne deciderà la partecipazione), facendoci carico delle spese relative all'iscrizione al congresso, al viaggio ed al soggiorno. Il congresso, di natura prettamente scientifica, sarà un'ottima occasione per tutti i partecipanti per incontrarsi, scambiare idee nonché un aggiornamento su tutti gli aspetti inerenti le materie trattate.

Vi comuniciamo che trascorsi 30 giorni dalla data della presente, nulla ricevendo da parte Vostra, riterremo accettato il nostro invito.

Vi informiamo inoltre che al partecipante designato sarà inviata una lettera di conferma di sovvenzione, come da esempio allegato.

Edwards Lifesciences Italia S.p.A.  
 Angelo Trapani Business Unit Manager

**BRUNO LOI**  
**FRANCESCO SANNA**


**GIUSEPPE DEL PRETE**


Azienda Ospedaliera Brotzu  
 S.C. di Cardiocirurgia  
 Direzione (fax 070539752)

NOME e COGNOME: **GIUSEPPE DEL PRETE**  
 FUNZIONE: **DIR. MED. D.**

DATA: **19.07.16** TIMBRO: **AZIENDA OSPEDALIERA G. BROTZU S.C. CARDIOCIRURGIA IL DIRETTORE**

IL DIRETTORE DEL DIPARTIMENTO  
 PATOLOGIA CARDIACA  
 Dott. Maurizio Porcu





Edwards

AO BROTZU

PG/2016/ 0016122 del 22/07/2016 ore 08,17

Mittente EDWARDS LIFESCIENCES ITALIA SPA

Assegnatario DIREZIONE SANITARIA



Spettabile

Azienda Ospedaliera G. Brotzu

Piazzale Alessandro Ricchi,  
1, 09134 Cagliari

c.a.: Direzione Sanitaria

p.c. Primario del reparto di Cardiocirurgia

Milano, 21 LUG 2015

**AZIENDA OSPEDALIERA G. BROTZU**  
**UFFICIO FORMAZIONE**  
*Autore*

OGGETTO: PCR London Valves 18 - 20 settembre 2016 (Londra)

La nostra Società parteciperà all'iniziativa in oggetto; fermo restando il rispetto della normativa del Ministero della Sanità in merito ai fini autorizzativi e procedurali, siamo lieti di invitare: n° 1 cardiocirurgo e n° 2 cardiologi interventisti che il Primario di Reparto vorrà segnalarci (dei quali la Vs. Amministrazione in piena e totale autonomia ne deciderà la partecipazione), facendoci carico delle spese relative all'iscrizione al congresso, al viaggio ed al soggiorno. Il congresso, di natura prettamente scientifica, sarà un'ottima occasione per tutti i partecipanti per incontrarsi, scambiare idee nonché un aggiornamento su tutti gli aspetti inerenti le materie trattate.

Vi comunichiamo che trascorsi 30 giorni dalla data della presente, nulla ricevendo da parte Vostra, riterremo accettato il nostro invito.

Vi informiamo inoltre che al partecipante designato sarà inviata una lettera di conferma di sovvenzione, come da esempio allegato.

**BRUNO LOI**  
**FRANCESCO SANNA**

Edwards Lifesciences Italia S.p.A.  
Angelo D'Amico Business Unit Manager

Azienda Ospedaliera Brotzu  
S.C. di  
Direttore

**GIUSEPPE DEL PRETE**

Per accettazione da parte della Direzione Sanitaria/Amministrativa (da inviare al numero di fax 02/56806595):

NOME e COGNOME:

FUNZIONE:

DATA:

TIMBRO:

**AZIENDA OSPEDALIERA "G. BROTZU"**

**S.C. CARDIOCHIRURGIA**

**IL DIRETTORE**

**Dot. Emiliano Maria CIRIO**

**AZIENDA OSPEDALIERA "G. BROTZU"**  
**CAGLIARI**  
**S.C. CARDIOCHIRURGIA**  
**IL DIRETTORE**  
**Dot. Emiliano Maria CIRIO**

IL DIRETTORE DEL DIPARTIMENTO  
PATOLOGIA CARDIACA  
Dot. Maurizio Porcu



Edwards Lifesciences Italia S.p.A.  
Sede Legale: Centro Leoni Edificio A - Via Giovanni Spadolini, 5 - 20141 Milano  
Tel. 02.56806.1 - Fax 02.56806.692 - www.edwards.com

P.I.C.F. 06068041000 - Capitale Sociale Euro 104.336,73 Int. vers. - Reg. Imprese Milano 06068041000 - R.E.A. 16298

*in allegato*


**IL DIRETTORE DEL DIPARTIMENTO**  
**PATOLOGIA CARDIACA**  
**Dot. Maurizio Porcu**

🕒 18-20 September 2016

📍 ExCEL London  
London, United Kingdom

# Programme

*Valid as of 05 August 2016*



PCR London Valves is an official EAPCI Course on Valves

*Designations used by companies to distinguish their products are often claimed as trademarks.  
All brand names and product names used in this programme are trade names, service marks,  
trademarks or registered trademarks of their respective owners.*

- 11:00 -

**11:00 - 12:00** ■ **Taking TAVI to the next level  
with imaging**

ROOM 2

Plenary

**Chairpersons: M. Monaghan, N. Piazza**  
**Panellists: A. Latib, S. Redwood, S. Saito,**  
**J. Zamorano**

**Attend this session if you want:**

- › To fully understand how state-of-the-art imaging can predict outcomes and reduce complications after TAVI
- › To learn how to achieve optimal deployment depth during TAVI
- › To appreciate the fundamental role of imaging during post-procedural follow-up

- 11:00 › Session objectives  
*N. Piazza*
- 11:04 › Predicting the outcome of valve implantation with echocardiography - where are we?  
*J. Hancock*
- 11:11 › Time to React@PCR
- 11:17 › Predicting the outcome of valve implantation with CT - current and future possibilities  
*J. Leipsic*
- 11:24 › Time to React@PCR
- 11:30 › Optimal device positioning to reduce procedural complications - the double S curve  
*D. Mylotte*
- 11:37 › Time to React@PCR
- 11:43 › Valve imaging during follow-up - normal and abnormal findings  
*R. Hahn*
- 11:50 › Time to React@PCR
- 11:56 › Session evaluation and key learnings  
*M. Monaghan*

- 12:00 -

12:30 - 12:35 **Welcome and introduction**

PCR  
INNOVATORS  
DAY - ROOM 5  
PCR Innovators  
Day

**Attend PCR Innovators Day if you want::**

- > To fully understand how percutaneous valve technology moves from concept to first-in-man use
- > To learn more about innovations in percutaneous valve interventions
- > To network with clinicians, innovators, MedTech executives, investors, triallists, and regulators in the field of percutaneous valve intervention

- 12:30 > Welcome to PCR Innovators Day @ London Valves  
*B. Prendergast*

12:35 - 13:30 **Theme 1: innovation in percutaneous mitral valve repair**

PCR  
INNOVATORS  
DAY - ROOM 5  
PCR Innovators  
Day

**Chairpersons:** *A. Latib, F. Maisano*  
**Panellists:** *M. Darnaud, G. Nickenig (Pending approval), D. O'Mahony (Pending approval)*

- 12:35 > Introduction - percutaneous mitral valve repair in 2016: unmet needs and future perspectives?  
*A. Vahanian*
- 12:45 **Innovations in focus: mitral valve repair**  
> Mitraclamp - an effective solution to repair mitral valve prolapse  
*R. Zegdi*
- 12:53 > Discussion and audience interaction
- 13:00 > Valcare mitral annuloplasty: from concept to first-in-human experience  
*A. Segev*
- 13:08 > Discussion and audience interaction
- 13:15 > Middle Peak Medical: a semi-repair and semi-replacement technique  
*A. Khairkahan (Pending approval)*
- 13:23 > Discussion and audience interaction

12:35 - 13:35 **Imaging of the mitral valve complex for transcatheter interventions**

ROOM 2  
Plenary

**Chairpersons:** *I. Meredith, L. Sondergaard*  
**Panellists:** *J. Hancock (Pending approval), T. Lefèvre, T. Modine, K.K. Yeo*

**Attend this session if you want:**

- > To fully understand the anatomical complexity of the mitral valve
- > To appreciate the complementary roles of echocardiography and CT before, during and after transcatheter mitral valve interventions
- > To become familiar with the imaging characteristics of the current range of percutaneous mitral devices

- 12:35 > Session objectives  
*I. Meredith*
- 12:39 > The anatomical and physiological complexity of the mitral valve  
*V. Delgado*
- 12:46 > Time to React@PCR
- 12:52 > Echocardiographic assessment of mitral regurgitation before, during and after intervention  
*M. Monaghan*
- 12:59 > Time to React@PCR
- 13:05 > Detailed planning of transcatheter mitral interventions using CT  
*J. Leipsic*
- 13:12 > Time to React@PCR
- 13:18 > Imaging appearances of currently available devices - a user's guide  
*S. Von Bardeleben*
- 13:25 > Time to React@PCR
- 13:31 > Session evaluation and key learnings  
*L. Sondergaard*

- 14:00 -

14:10 - 14:20 **PCR Innovators Day @ London Valves - A word from our sponsors**

PCR  
INNOVATORS  
DAY - ROOM 5  
PCR Innovators  
Day

- 14:10 > IMMR presentation  
*N. Borenstein (Pending approval)*
- 14:13 > HTI BioQuest presentation  
*E. Howard (Pending approval)*
- 14:16 > genae presentation  
*A. Talen*

14:20 - 15:15  
PCR  
INNOVATORS  
DAY - ROOM 5

PCR Innovators  
Day

**Theme 2: innovation in percutaneous mitral valve replacement**

*Chairpersons: V. Bapat, R. Kornowski*  
*Panellists: M. Mack, I. Meredith, A. Papiernik (Pending approval), A. Schmitz*

- 14:20 > Introduction - percutaneous mitral valve replacement in 2016: unmet needs and future perspectives?  
*N. Piazza (Pending approval)*
- Innovations in focus : mitral valve replacement**
- 14:30 > The Caisson transcatheter mitral valve replacement system  
*M. Williams (Pending approval)*
- 14:38 > Discussion and audience interaction
- 14:45 > The Cephea transcatheter mitral valve replacement system
- 14:53 > Discussion and audience interaction
- 15:00 > QUATTOR - a four leaflet elliptical transcatheter mitral valve  
*G. Agreli (Pending approval)*
- 15:08 > Discussion and audience interaction

14:35 - 15:35  
ROOM 3



**Imaging for TAVI: Live CT analysis and interpretation for correct device selection and sizing**

*Facilitators: J. Leipsic, D. Mylotte*  
*Media Driver: P. Thériault-Lauzier*  
*Expert Panellist: T. Modine*

- Attend this session if you want:**
- > To learn how to analyse a CT scan of the aortic valvar complex prior to TAVI
  - > To understand which clinical and anatomical variables are important for both patient and device selection
  - > To appreciate the differences in CT analysis between bicuspid and tricuspid aortic valves and how this may influence patient and device selection

- 15:00 -

15:45 - 16:45  
ROOM 3



**Imaging for MitraClip Interventions: pre- and intra-procedural imaging**

*Facilitators: F. Maisano, S. Von Bardeleben (Pending approval)*  
*Media Driver: J. Joseph*  
*Expert Panellist: V. Delgado*

**Attend this session if you want:**

- > To learn echocardiographic inclusion/exclusion criteria for patients with either primary or secondary mitral regurgitation undergoing MitraClip implantation
- > To learn the key aspects of intra-procedural echocardiography for MitraClip positioning and deployment
- > To better recognise when and how to deploy a "second" clip

15:55 - 16:50  
PCR  
INNOVATORS  
DAY - ROOM 5

PCR Innovators  
Day

**Theme 3: innovation in percutaneous tricuspid valve intervention**

*Chairpersons: S. Bolling, C. Tamburino*  
*Panellists: J. Eadie (Pending approval), R. Lange, J. Schofer, P.W. Serruys*

- 15:55 > Introduction - percutaneous tricuspid valve intervention in 2016: unmet needs and future perspectives?  
*S. Windecker (Pending approval)*
- Innovations in focus : the tricuspid valve**
- 16:05 > The Innovocentric solution for tricuspid regurgitation
- 16:13 > Discussion and audience interaction
- 16:20 > Valtech Cardioband - an established device with a new delivery system  
*A. Gross (Pending approval)*
- 16:28 > Discussion and audience interaction
- 16:35 > TRiCares - a dedicated tricuspid transcatheter heart valve  
*H.J. Straubinger (Pending approval)*
- 16:43 > Discussion and audience interaction

- 16:00 -

- 16:45 - 17:45**  
ROOM 2  
Plenary
- Advanced imaging modalities to guide transcatheter valve interventions**
- Chairpersons: V. Delgado, N. Van Mieghem*  
*Panellists: A. Baumbach, R. Hahn, S. Von Bardeleben, J. Webb*  
*React@PCR Moderator: D. Natarajan (Pending approval)*
- Attend this session if you want:**
- > To appreciate the rapidly evolving role of imaging in facilitating transcatheter valve interventions
  - > To understand how intracardiac echocardiography and transnasal echocardiography can simplify transcatheter valve procedures
  - > To know more about the future of imaging in the cathlab environment
- 16:45 > Session objectives  
*V. Delgado*
- 16:49 > Rotational CT - an imaging "one-stop shop"  
*P. Thériault-Lauzier*
- 16:56 > Time to React@PCR
- 17:02 > Intracardiac echocardiography: pros and cons  
*L. Sondergaard*
- 17:09 > Time to React@PCR
- 17:15 > Transnasal echocardiography: pros and cons  
*M. Monaghan*
- 17:22 > Time to React@PCR
- 17:28 > Fusion imaging: current and future possibilities  
*J. Zamorano*
- 17:35 > Time to React@PCR
- 17:41 > Session evaluation and key learnings  
*N. Van Mieghem*

- 16:50 - 17:35**  
PCR  
INNOVATORS  
DAY - ROOM 5  
PCR Innovators  
Day
- Keynote lecture and round table discussion**
- Moderators: D. Cassak (Pending approval), S. Levin (Pending approval)*
- > Introduction  
*D. Cassak (Pending approval)*
  - > The value of innovation: perspectives from the worldwide financial markets  
*L. Biegelsen*
  - > Who (if anyone) wil win in mitral valves? Lessons learnt from the TAVI success story  
*M. Rothman*

- 17:00 -


- 17:35 - 17:45**  
PCR  
INNOVATORS  
DAY - ROOM 5  
PCR Innovators  
Day
- Concluding remarks**
- Speaker: N. Piazza (Pending approval)*



- 18:00 -

- 18:00 - 19:40**  
MAIN ARENA  
Tools and  
Techniques
- TAVI IN 2016: the year the treatment of aortic stenosis was transformed**
- Sponsored by Edwards Lifesciences*  
*Chairpersons: G. Gerosa, S. Windecker*  
*Panellists: J. Baan (Pending approval), V. Falk, M. Gilard*  
*Operators: J. Hancock, B. Prendergast, S. Redwood*  
*React@PCR Moderator: D. Natarajan (Pending approval)*
- Attend this session if you want:**
- > To learn from the latest evidence in the field of TAVI
  - > To understand which patient populations would either benefit from surgical aortic valve replacement or TAVI
  - > To learn how the TAVI procedure can be further streamlined with new generation delivery systems and valves
- 18:00 > Session objectives  
*G. Gerosa*
- 18:02 > TAVI in 2016: what is the data that justifies transformational change?  
*M. Gilard*
- 18:12 > Time to React@PCR
- 18:17 > When should surgical aortic valve replacement still be considered in intermediate risk patients?  
*V. Falk*
- 18:27 > Time to React@PCR
- 18:32 **Recorded case from St. Thomas' Hospital - London, United Kingdom**
- 18:48 **LIVE demonstration from St. Thomas' Hospital - London, United Kingdom**
- 19:08 > Time to React@PCR
- 19:13 > Optimising the in-hospital patient pathway  
*J. Baan (Pending approval)*
- 19:23 > Time to React@PCR
- 19:28 > Optimising TAVI through technological innovation  
*S. Windecker*
- 19:38 > Session evaluation and key learnings  
*S. Windecker*




- 08:00 -

- 08:30 - 08:45**  **Welcome**  
 MAIN ARENA  
 Ceremony
- Chairpersons: B. Prendergast, S. Windecker*  
*Panellists: M. Chen, J. Fajadet, M. Haude, N. Piazza, S. Saito, C. Tamburino*
- 08:30 > Introduction to PCR London Valves  
*B. Prendergast*
  - 08:37 > PCR Family  
*W. Wijns*

- 08:45 - 09:30**  **LIVE demonstration from Clinique Pasteur - Toulouse, France**  
 MAIN ARENA
-  *Chairpersons: J. Fajadet, S. Windecker*  
*Panellists: M. Chen, M. Haude, N. Piazza, B. Prendergast, S. Saito, C. Tamburino*
- 08:45 > Overview of the tools to be used during the LIVE demonstration  
*C. Tamburino*
  - 08:50 **LIVE demonstration from Clinique Pasteur - Toulouse, France**
  - 09:20 > Time to React@PCR

- 09:00 -

- 09:30 - 10:00**  **Spotlight session: bioprosthetic valve durability**  
 MAIN ARENA  
 Plenary
- Chairpersons: B. Prendergast, S. Windecker (Pending approval)*  
*Panellists: M. Chen, J. Fajadet, M. Haude, N. Piazza, S. Saito, C. Tamburino*
- Attend this session if you want:**
- > To learn more about the latest data from randomised controlled trials and registries concerning the durability of bioprosthetic valves
  - > To fully understand the important statistical considerations when interpreting long term outcome data in current TAVI recipients
  - > To appreciate the important difference between clinical and device-related endpoints and the need for a standardised definition of bioprosthetic valve durability and failure
- 09:30 > Session objectives  
*B. Prendergast*
  - 09:33 > Clinically relevant definitions of bioprosthetic valve durability and failure - lessons from the surgical experience  
*H. Treede*
  - 09:39 > Durability of TAVI bioprostheses - data from the randomised trials and registries  
*H. Eltchaninoff*
  - 09:45 > The pitfalls of long term survival analysis - implications for the regulators and future studies
  - 09:51 > Time to React@PCR
  - 09:57 > Session evaluation and key learnings  
*S. Windecker (Pending approval)*

**09:30 - 10:30** ■ **Long-term outcomes after TAVI**

ROOM 2

Plenary

**Chairpersons:** R. Kornowski, H. Moellmann  
**Panellists:** J. Leipsic, M. Mack, T. Walther, A. Witkowski

**Attend this session if you want:**

- › To fully understand the mechanisms of transcatheter valve failure and comparisons with surgical bioprostheses
- › To know more about current thinking concerning the phenomenon of TAVI leaflet thickening and subclinical thrombosis
- › To identify ways in which TAVI may emerge as long-term treatment strategy in younger, low-risk patients

- 09:30 › Session objectives  
*H. Moellmann*
- 09:33 › How and why might transcatheter valves fail?  
*M. Gilard*
- 09:40 › Time to React@PCR
- 09:44 › TAVI durability and comparisons with surgery  
*C. Young*
- 09:51 › Time to React@PCR
- 09:55 › TAVI leaflet thickening and subclinical thrombosis: keep calm and carry on imaging  
*R. Makkar*
- 10:02 › Time to React@PCR
- 10:06 › Infective endocarditis following TAVI - incidence and outcomes  
*A. Latib*
- 10:13 › Time to React@PCR
- 10:17 › TAV in TAV - current reality and future feasibility  
*A. Colombo*
- 10:24 › Time to React@PCR
- 10:28 › Session evaluation and key learnings  
*R. Kornowski*

**09:30 - 10:30** ■ **Mitral and tricuspid valve interventions**

ROOM 4

Abstracts

*Session comprising selected PCR London Valves 2016 abstract submissions*

**Chairpersons:** C. Grasso, C. Hammerstingl  
**Panellists:** M. Buch, G. Yucel

- 09:30 › Lond16A-OP90 - Feasibility and efficacy of intracardiac echocardiography for percutaneous mitral valve edge-to-edge repair using the MitraClip system  
*M. Patel*
- 09:37 › Discussion and audience interaction
- 09:42 › Lond16A-OP87 - Mismatch between clinical benefit and functional capacity assessed by cardiopulmonary exercise test in MitraClip patients  
*G. Salerno (Pending approval)*
- 09:49 › Discussion and audience interaction
- 09:54 › Lond16A-OP13 - One year follow-up results of mitral valve transcatheter annuloplasty system for mitral reconstruction multicentre trial  
*S. Von Bardeleben (Pending approval)*
- 10:01 › Discussion and audience interaction
- 10:06 › Lond16A-OP29 - Mitral annulus calcification score on CT can identify patients with increased risk of persistent mitral regurgitation post-TAVI  
*S. Setiawan*
- 10:13 › Discussion and audience interaction
- 10:18 › Lond16A-OP41 - Transcatheter treatment of severe tricuspid regurgitation using the MitraClip system  
*J. Hausleiter*
- 10:25 › Discussion and audience interaction

**09:30 - 10:30** ■ **Learning transeptal: the true minimal invasive access?**

ROOM 3



**Facilitators:** F. Praz, A. Vahanian  
**Media Driver:** H. McConkey  
**Expert Panellist:** E. Brochet

**Attend this session if you want:**

- › To identify which patient is suitable for a transeptal approach to valve intervention
- › To learn how to perform transeptal puncture safely
- › To fully understand the principles of a step by step procedure

**09:30 - 10:30 ■ TAVI 1**

**INTERACTIVE  
CASE CORNER**

*Session comprising selected PCR London Valves  
2016 clinical case submissions*

**Facilitators: J. Byrne, F. Castriota**

Cases

- 09:30 > Lond16C-ICC003 - Feasibility of simultaneous rotational atherectomy and balloon aortic valvuloplasty  
*C.W. Lee*
- 09:37 > Lond16C-ICC006 - Aortic balloon valvuloplasty: a bridge to TAVI in multivalvular heart disease patients  
*G. Ghanem*
- 09:44 > Lond16C-ICC008 - TAVI in aortic stenosis with severe hypercapnia assisted with femoro-femoral cardiopulmonary bypass to facilitate gas exchange  
*J. Quintanilla*
- 09:51 > Lond16C-ICC016 - Left main - left anterior descending PCI and TAVI in cardiogenic shock  
*D. Tsikaderis*
- 09:58 > Lond16C-ICC031 - All-in-one procedure  
*P. Cervinka*
- 10:06 > Lond16C-ICC064 - Transfemoral aortic valve replacement in a patient with ascending aortic dilatation and horizontal aortic root  
*T. Xiong*
- 10:14 > Lond16C-ICC046 - Minimalist TAVI with balloon expandable valve in severe bicuspid aortic stenosis with difficult anatomy using intracardiac echo guidance  
*C. Undemir*
- 10:22 > Lond16C-ICC047 - The ultimate minimalist TAVI: transfemoral, fluoro-guided, conscious sedation, zero contrast  
*R. Kaple*

**09:30 - 10:30 ■ TAVI complications 5**

**ROOM 5**

*Session comprising selected PCR London Valves  
2016 clinical case submissions*

**Facilitator: H.L. Kao**

Cases

- 09:30 > Lond16C-ICC034 - TAVI in an extremely large and calcified bicuspid aortic valve: a tale of two valves  
*R. Kaple*
- 09:38 > Lond16C-ICC152 - Right coronary occlusion post TAVI treated by PCI  
*A.K. Chaurasia*
- 09:46 > Lond16C-ICC158 - A devastating valve-in-valve complication: we did not expect coronary obstruction with that transcatheter heart valve  
*D. Dvir*
- 09:54 > Lond16C-ICC145 - Acute exacerbation of mitral stenosis after transcatheter aortic valve replacement  
*Y. Fuku*
- 10:03 > Lond16C-ICC160 - Left-to-right shunt post-TAVI  
*V. Sullivan*
- 10:12 > Lond16C-ICC162 - Double valve-in-valve leading to double complication  
*D. Dvir*
- 10:21 > Lond16C-ICC169 - Pop-in: unusual valve movement  
*E. Ercan*

**- 10:00 -**

**10:00 - 10:30 ■ Keynote lecture**

**MAIN ARENA**

**Chairpersons: N. Piazza, C. Tamburino**

Keynote lecture

- 10:00 > Introduction  
*C. Tamburino*
- 10:02 > The tricuspid valve - forgotten and neglected (until now)  
*S. Bolling*
- 10:28 > Note of thanks  
*N. Piazza*

- 11:00 -

<p><b>11:00 - 11:45</b> MAIN ARENA Plenary</p>	<p><b>Moving TAVI to lower-risk populations</b> <i>Chairpersons: D. Mylotte, O. Wendler</i> <i>Panellists: S. Ajay, J. Byrne, A. Colombo, A. Cribier, R. Lange, M.B. Leon</i> <i>React@PCR Moderator: S. Cannata (Pending approval)</i></p> <p><b>Attend this session if you want:</b></p> <ul style="list-style-type: none"> <li>&gt; To understand which younger low-risk patient may benefit from TAVI</li> <li>&gt; To learn how case selection for TAVI will change in a lower risk patient group</li> <li>&gt; To appreciate the unmet needs of TAVI in younger patients</li> </ul> <p>11:00 &gt; Session objectives <i>O. Wendler</i></p> <p>11:05 &gt; High-risk and low-risk patients - what are the real differences? <i>L. Sondergaard</i></p> <p>11:10 &gt; Time to React@PCR</p> <p>11:14 &gt; The limitations of surgery in low-risk patients - an interventionist's perspective <i>S. Windecker</i></p> <p>11:19 &gt; Time to React@PCR</p> <p>11:23 &gt; The limitations of TAVI in low-risk patients - a surgeon's perspective <i>N. Moat</i></p> <p>11:28 &gt; Time to React@PCR</p> <p>11:32 &gt; Should the perspective of the Heart Team now change? <i>J. Webb</i></p> <p>11:37 &gt; Time to React@PCR</p> <p>11:41 &gt; Session evaluation and key learnings <i>D. Mylotte</i></p>
--	---

<p><b>11:00 - 12:30</b> ROOM 2 Plenary</p>	<p><b>RAPID FIRE: innovations in percutaneous mitral intervention</b> <i>Chairpersons: I. Meredith, C. Tamburino</i> <i>Panellists: M. Buch, H. Ince, M. Mack, C.K. Naber</i></p> <p><b>Attend this session if you want:</b></p> <ul style="list-style-type: none"> <li>&gt; To fully understand the anatomical and technical challenges associated with percutaneous mitral intervention</li> <li>&gt; To hear the latest outcome data concerning cutting edge technologies with first-in-man experience</li> <li>&gt; To identify the limitations of currently available devices</li> </ul> <p>11:00 &gt; Session objectives <i>C. Tamburino</i></p> <p>11:03 &gt; What are the anatomical and technical challenges in percutaneous mitral intervention? <i>E. Grube</i></p> <p><b>Percutaneous mitral valve repair</b></p> <p>12:21 &gt; What does the future hold? <i>T. Feldman</i></p> <p>12:27 &gt; Session evaluation and key learnings <i>I. Meredith</i></p>
--	--

<p><b>11:00 - 12:30</b> ROOM 3 </p>	<p><b>Learning mitral valve-in-valve, valve-in-ring and MAC: "old" techniques, new indications</b> <i>Facilitators: V. Bapat, V. Delgado</i> <i>Media Driver: J. Joseph</i> <i>Expert Panellist: N. Piazza</i></p> <p><b>Attend this session if you want:</b></p> <ul style="list-style-type: none"> <li>&gt; To fully understand the key factors determining patient and procedural selection</li> <li>&gt; To learn the principles of device selection and sizing for each technique</li> <li>&gt; To appreciate the importance of multimodality imaging in minimising LVOT obstruction</li> </ul>
--	--

**11:00 - 12:30** ■ **International Forum 1:**

ROOM 4

Cases

**UK-Germany share their most educational cases**

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Chairpersons: M. Haude, D. Hildick-Smith**  
**Panellists: M. Mullen (Pending approval), J. Schofer, S. Von Bardeleben (Pending approval)**

- 11:00 > Lond16C-OP028 - Successful concomitant transcatheter valve implantation and alcohol septal ablation in a patient with symptomatic aortic valve stenosis and hypertrophic cardiomyopathy  
*V. Rudolph*
- 11:08 > Discussion and audience interaction
- 11:15 > Lond16C-OP159 - Percutaneous pulmonary valve implantation in an orthotopic heart transplant recipient  
*A. Bhan*
- 11:23 > Discussion and audience interaction
- 11:30 > Lond16C-OP057 - Emergency paravalvular leak closure for aortic regurgitation following implantation of "new-generation" self-expandable transcatheter aortic valve prosthesis  
*M. Vasa-Nicotera*
- 11:38 > Discussion and audience interaction
- 11:45 > Lond16C-OP078 - An interesting complication following implantation of a transcatheter valve in mitral annular calcification with a creative improvised surgical solution  
*M. Ghosh-Dastidar*
- 11:53 > Discussion and audience interaction
- 12:00 > Lond16C-OP138 - Percutaneous edge-to-edge tricuspid valve repair for treatment of severe regurgitation  
*E.W. Holy*
- 12:08 > Discussion and audience interaction
- 12:15 > Lond16C-OP148 - Coronary occlusion during TAVI: triumphs and disasters  
*S. Dawkins*
- 12:23 > Discussion and audience interaction

**11:00 - 12:30** ■ **TAVI 2**

INTERACTIVE CASE CORNER

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators: H. Degen, Ö. Göktekin (Pending approval)**

Cases

- 11:00 > Lond16C-ICC117 - TAVI as redo therapy after initial surgery for aortic dissection  
*G. Dahle*
- 11:09 > Lond16C-ICC074 - The vulnerable neighbor: recover from severe mitral regurgitation caused by TAVI  
*Y. Li*
- 11:18 > Lond16C-ICC075 - Old female with severe aortic stenosis and significant anemia  
*R. Garcia-Borbolla Fernández*
- 11:27 > Lond16C-ICC094 - Balloon expandable TAVI in a patient with previous mitral valve replacement  
*A. Higashimori*
- 11:36 > Lond16C-ICC068 - Benefit of TAVI with a recapturable and repositionable bioprosthesis in a patient with oval shaped aortic annulus  
*J. Valle Raleigh*
- 11:45 > Lond16C-ICC121 - Percutaneous valve implantation in a congenital heart with degenerated homograft in both aortic and pulmonic position  
*J. Kefer*
- 11:54 > Lond16C-ICC135 - Contrast-induced nephropathy is not the only cause of acute kidney injury after TAVI!  
*A. Allali*
- 12:03 > Lond16C-ICC029 - Insights into frailty assessment: TAVI in a 100-year-old patient  
*G. Latsios*
- 12:12 > Lond16C-ICC125 - Prediction and evaluation of TAVI with patient-specific computer simulation: a case example  
*N. El Faquir*
- 12:21 > Lond16C-ICC128 - Valve-in-valve: determination of sizing while performing the case  
*A. Merino Rajme*

**11:00 - 12:30 TAVI valve in valve**

ROOM 5

*Session comprising selected PCR London Valves 2016 clinical case submissions*

Cases

**Facilitators: F. Castriota, D. Dvir**

- 11:00 > Lond16C-ICC011 - Successful sheathless implantation of a transfemoral valve-in-valve transcatheter aortic valve replacement for failed bioprosthetic valve  
*R. Anantharaman*
- 11:09 > Lond16C-ICC060 - Combined structural heart disease interventions in a failed bioprosthesis: the Janus procedure  
*N. Amabile*
- 11:18 > Lond16C-ICC062 - Valve-in-valve: unplugged  
*H. McConkey*
- 11:27 > Lond16C-ICC103 - TAVI: valve-in-valve in degenerate aortic homograft root replacement using a direct flow medical device  
*A. Duncan*
- 11:36 > Lond16C-ICC140 - A dislodged sutureless aortic valve  
*A. Cassar*
- 11:45 > Lond16C-ICC141 - Transfemoral aortic valve-in-valve implantation using a balloon-expandable transcatheter valve for failed surgical stentless bioprosthesis  
*S. Mauri*
- 11:54 > Lond16C-ICC156 - Valve-in-valve challenges: we should not rely on the central marker!  
*D. Dvir*
- 12:03 > Lond16C-ICC119 - Concomitant transapical TAVI and catheter valve in mitral annular calcification  
*G. Dahle*
- 12:12 > Lond16C-ICC157 - Challenging valve-in-valve TAVI using a fully repositionnable mechanically expanding prosthesis  
*M. El-Mawardy*
- 12:21 > Lond16C-ICC164 - Perfect is the enemy of good: challenges while trying to optimise haemodynamics of aortic valve-in-valve  
*D. Dvir*

**- 14:00 -**

**14:45 - 16:15 Learning MitraClip: how to succeed?**

ROOM 3



**Facilitators: E. Brochet, H. Ince**  
**Media Driver: H. McConkey**  
**Expert Panellist: C. Hammerstingl**

**Attend this session if you want:**

- > To fully understand the range of mitral valve anatomy suitable for a percutaneous mitral "edge-to-edge" repair procedure
- > To learn the key tips and tricks for a successful outcome
- > To appreciate how to avoid and manage potential complications of the procedure

**11:45 - 12:30 LIVE demonstration from St. Thomas' Hospital - London, United Kingdom**

MAIN ARENA



**Chairpersons: D. Mylotte, O. Wendler**  
**Panellists: S. Ajay, J. Byrne, A. Colombo, A. Cribier, R. Lange, M.B. Leon**  
**React@PCR Moderator: S. Cannata**  
*(Pending approval)*

- 11:45 > Overview of the tools to be used during the LIVE demonstration  
*J. Byrne (Pending approval)*
- 11:50 **LIVE demonstration from St. Thomas' Hospital - London, United Kingdom**
- 12:20 > Time to React@PCR

- 13:00 -

**13:00 - 13:45**  
ROOM 2

Symposium



**The Lotus Valve: simplifying real-world practice**

*Sponsored by Boston Scientific*

**Chairpersons: T. Feldman, L. Sondergaard**

**Panellists: V. Bapat, D. Blackman, M. Göteborg, J. Wöhrle**

**Attend this session if you want:**

- › To understand the current evidence and latest clinical data
- › To learn how paravalvular leak can be minimised despite anatomical complexities
- › To recognise how Lotus Edge can advance practice in key patient subsets

- 13:00 › Session objectives  
*L. Sondergaard*
- 13:03 › The latest clinical evidence  
*D. Blackman*
- 13:11 › Discussion and audience interaction
- 13:16 › Why Lotus is my workhorse valve  
*J. Wöhrle*
- 13:24 › Discussion and audience interaction
- 13:29 › Lotus Edge: advancing clinical practice  
*M. Göteborg*
- 13:37 › Discussion and audience interaction
- 13:42 › Session evaluation and key learnings  
*T. Feldman*

**13:00 - 14:40**  
ROOM 3

Tools and Techniques



**Applications, indications and outcomes of transcatheter mitral annuloplasty**

*Sponsored by Cardiac Dimensions*

**Chairpersons: I. Meredith, H. Sievert**

**Panellists: M. Haude, S. Von Bardeleben, K. Witte**

**Attend this session if you want:**

- › To learn about the multiple applications of transcatheter mitral annuloplasty
- › To learn a systematic approach to the selection of appropriate candidates
- › To observe demographic analysis of the first randomised, blinded trial in the field of functional mitral regurgitation

- 13:00 › Session objectives  
*I. Meredith*
- 13:05 **Recorded case from Städtische Kliniken Neuss, Lukaskrankenhaus - Neuss, Germany**  
*M. Haude*
- 13:25 › Discussion and audience interaction
- 13:31 › When to intervene with transcatheter annuloplasty in a functional mitral regurgitation population  
*K. Witte*
- 13:43 › Discussion and audience interaction
- 13:49 **Recorded case from Universitätsmedizin Mainz University - Mainz, Germany**  
*S. Von Bardeleben*
- 14:09 › A multimodal approach to the treatment of functional mitral regurgitation  
*S. Von Bardeleben*
- 14:17 › Discussion and audience interaction
- 14:23 › The landmark REDUCE FMR trial: first randomised, blinded evaluation of transcatheter annuloplasty in functional mitral regurgitation  
*M. Haude*
- 14:31 › Discussion and audience interaction
- 14:37 › Session evaluation and key learnings  
*H. Sievert*

**13:00 - 13:45** ■ **MitraClip NT: the next frontier**

ROOM 4

Symposium



*Sponsored by Abbott*

**Chairpersons:** *F. Maisano, A. Vahanian*  
**Panellists:** *J. Van Der Heyden, S. Von Bardeleben*

**Attend this session if you want:**

- › To learn about the new developments and data in mitral interventions
- › To learn how MitraClip NT can help to expand the potential patient population and reduce procedural time
- › To learn tips and tricks on treating complex anatomy with MitraClip NT

- 13:00 › Session objectives  
*A. Vahanian*
- 13:05 › What is the future in mitral regurgitation interventions?  
*F. Maisano*
- 13:13 › How far can you go with MitraClip NT?
- 13:13 › Case 1  
*S. Von Bardeleben*
- 13:18 › Discussion and audience interaction
- 13:22 › Case 2  
*J. Van Der Heyden*
- 13:27 › Discussion and audience interaction
- 13:31 › Case 3  
*F. Maisano*
- 13:36 › Discussion and audience interaction
- 13:40 › Session evaluation and key learnings  
*F. Maisano*

**13:55 - 14:40** ■ **Portico - when expertise meets simplicity: key learnings**

ROOM 2

Case in Point



*Sponsored by St. Jude Medical*

**Chairpersons:** *G. Fontana, H. Moellmann*  
**Panellists:** *A. Linke, R. Makkar, F. Nietlispach, L. Sondergaard*

**Attend this session if you want:**

- › To learn about the latest worldwide developments with the St. Jude Medical Portico valve
- › To learn on Portico the first to innovate with fully recapturable valve
- › To review and discuss a selection of complex TAVI cases and how Portico helped in solving them

- 13:55 › Session objectives  
*H. Moellmann*
- 13:58 › Advancing the science and evidence-based medicine of heart valves: Portico clinical programme update  
*L. Sondergaard (Pending approval)*
- 14:03 › Time to React@PCR
- 14:11 › Solopath: the use of the Solopath re-collapsible sheath for challenging femoral access with the Portico transcatheter valve  
*A. Linke (Pending approval)*
- 14:16 › Time to React@PCR
- 14:24 › Why is Portico the valve of choice for these types of indications?  
*F. Nietlispach*
- 14:29 › Time to React@PCR
- 14:37 › Session evaluation and key learnings  
*G. Fontana*



**13:55 - 14:40** ■ **SYMETIS TAVI: latest results and future clinical outlooks**

ROOM 4

Symposium



*Sponsored by Symetis*

**Chairpersons: W.K. Kim, S. Windecker**

**Attend this session if you want:**

- › To be informed about the latest results from the SAVI TF registry (30 days and one-year data)
- › To learn on the device performance of the ACURATE neo in patients with small annuli (sub-analysis of SAVI TF)
- › To appreciate patient population changes with more intermediate and low risk patients treated (NOTION I and II)

- 13:55 › Session objectives  
*S. Windecker*
- 14:00 › ACURATE neo technology and clinical update (SAVI TF data at 30 days and one year)  
*W.K. Kim*
- 14:12 › Discussion and audience interaction
- 14:15 › SAVI TF sub-analysis: device performance in small annuli  
*T. Rudolph*
- 14:22 › Discussion and audience interaction
- 14:25 › Optimising outcomes and shift to new patient populations  
*L. Sondergaard (Pending approval)*
- 14:32 › Discussion and audience interaction
- 14:35 › Session evaluation and key learnings  
*T. Walther*

**- 14:00 -**

**14:45 - 15:30** ■ **LIVE demonstration from St. Thomas' Hospital - London, United Kingdom**

MAIN ARENA



**Chairpersons: M. Haude, M. Mack**  
**Panellists: J.J. Bax, V. Falk, T. Feldman, I. Meredith, G. Nickenig, H. Treede**

- 14:45 › Overview of the tools to be used during the LIVE demonstration  
*I. Meredith (Pending approval)*
- 14:50 **LIVE demonstration from St. Thomas' Hospital - London, United Kingdom**
- 15:20 › Time to React@PCR

**14:45 - 16:15** ■ **All you need to know about the tricuspid valve**

ROOM 2



**Chairpersons: R. Lange, P. Pibarot**  
**Panellists: S. Bolling, A. Latib, M. Monaghan, J. Schofer**

**Attend this session if you want:**

- › To improve your understanding of the anatomy and pathophysiology of the tricuspid valve
- › To learn how to evaluate the mechanism and severity of tricuspid regurgitation using multimodality imaging
- › To appreciate the current status of tricuspid valve surgery and alternative percutaneous treatment options

- 14:45 › Session objectives  
*P. Pibarot*
- 14:50 › Tricuspid valve anatomy and pathophysiology - what do interventional cardiologists and surgeons need to know?  
*O. Wendler*
- 14:58 › Time to React@PCR
- 15:06 › Current recommendations for the treatment of secondary tricuspid regurgitation  
*A. Vahanian*
- 15:14 › Time to React@PCR
- 15:22 › Multimodality imaging of the tricuspid valve and right ventricle before surgery and percutaneous intervention  
*R. Hahn*
- 15:30 › Time to React@PCR
- 15:38 › Surgery in secondary tricuspid regurgitation - surgical techniques and their limitations  
*T. Modine*
- 15:46 › Time to React@PCR
- 15:54 › Percutaneous alternatives - current options and future prospects  
*F. Maisano*
- 16:02 › Time to React@PCR
- 16:10 › Session evaluation and key learnings  
*R. Lange*

**14:45 - 16:15** ■ **International Forum 2: Italy-USA**

ROOM 4

Cases

**share their most educational cases**

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Chairpersons: M.B. Leon, A.S. Petronio**  
**Panellists: F. Bedogni, F. Castriota, R. Makkar**

- 14:45 > Lond16C-OP013 - MitraClip and tricuspid regurgitation: different new approaches for a "classic" device  
*P. Denti*
- 14:53 > Discussion and audience interaction
- 15:00 > Lond16C-OP153 - MitraClip therapy: an alternative treatment for haemolytic anemia induced by mitral para-annuloplasty ring leak  
*Z. Wang*
- 15:08 > Discussion and audience interaction
- 15:15 > Lond16C-OP035 - When a wire trips your valve: a shocking nightmare in the cathlab  
*C. Moretti*
- 15:23 > Discussion and audience interaction
- 15:30 > Lond16C-OP044 - Leaflet overhang as possible mechanism of late structural failure of first-generation balloon expandable transcatheter heart valve treated with valve-in-valve with latest generation balloon expandable valve  
*G. Tang*
- 15:38 > Discussion and audience interaction
- 15:45 > Lond16C-OP097 - A new indication for another self-expanding TAVI prosthesis  
*P. Pagnotta*
- 15:53 > Discussion and audience interaction
- 16:00 > Lond16C-OP143 - Imaging in percutaneous tricuspid leaflet repair  
*S. Gafoor*
- 16:08 > Discussion and audience interaction

**14:45 - 15:30** ■ **Why is the mitral valve so different to the aortic?**

ROOM 5

Focus Nurses and Allied Professionals

Plenary

**Chairpersons: M. Gilard, K. Wilson**

**Attend this session if you want:**

- > To improve your knowledge of the anatomy and physiology of the mitral valve
  - > To better understand how to diagnose mitral valve disease and identify triggers for intervention
  - > To appreciate the different surgical and percutaneous approaches that can be used for the treatment of mitral valve disease
- 
- 14:45 > Session objectives  
*K. Wilson*
  - 14:48 > Anatomy and physiology of the normal mitral valve  
*P. Almeida*
  - 14:54 > Time to React@PCR
  - 14:58 > The spectrum of mitral valve disease - symptoms and diagnosis  
*D. Sparv*
  - 15:04 > Time to React@PCR
  - 15:08 > Assessing severity and when to intervene  
*K. Victor*
  - 15:14 > Time to React@PCR
  - 15:18 > Surgical and percutaneous treatment options  
*M. Buch*
  - 15:24 > Time to React@PCR
  - 15:28 > Session evaluation and key learnings  
*M. Gilard*

**14:45 - 15:30** ■ **TAVI complications 1**

**INTERACTIVE CASE CORNER**

Cases

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators: F. Hellig, D. Hildick-Smith**

- 14:45 > Lond16C-ICC009 - Pericardial effusion after transfemoral TAVI with lethal outcome  
*W.K. Kim*
- 14:52 > Lond16C-ICC032 - Successful treatment of aortic rupture after TAVI with stent graft  
*P. Cervinka*
- 14:59 > Lond16C-ICC037 - Three self-expandable prosthesis  
*M.C. Ferrer-Gracia*
- 15:07 > Lond16C-ICC039 - Is it really feasible or safe? Transcatheter retraction of migrated prosthesis into left ventricular outflow tract during TAVI  
*D. Hachinohe*
- 15:15 > Lond16C-ICC040 - What is this new jet? Acquired aorto right ventricular fistula after balloon expandable TAVI  
*C. Undemir*
- 15:23 > Lond16C-ICC052 - Double pop out after valve-in-valve implantation  
*G. Sardella*

- 15:00 -

<b>15:30 - 16:15</b>	<b>Mitral valve anatomy: implications for percutaneous interventions</b>
MAIN ARENA	
Plenary	
	<i>Chairpersons: M. Haude, M. Mack</i>
	<i>Panellists: J.J. Bax, V. Falk, T. Feldman, I. Meredith, G. Nickenig, H. Treede</i>
	<b>Attend this session if you want:</b>
	<ul style="list-style-type: none"> <li>› To fully understand normal mitral valve anatomy and physiology</li> <li>› To appreciate the pathophysiology of mitral regurgitation and different degrees of anatomical involvement</li> <li>› To identify the anatomical boundaries guiding different interventional treatments</li> </ul>
15:30	› Session objectives <i>M. Haude</i>
15:33	› Mitral valve anatomy and pathophysiology: determinants of correct treatment selection <i>V. Delgado</i>
15:38	› Time to React@PCR
15:43	› Anatomical challenges for percutaneous mitral edge-to-edge repair <i>C. Grasso</i>
15:48	› Time to React@PCR
15:53	› Anatomical challenges for percutaneous mitral annuloplasty <i>S. Von Bardeleben</i>
15:58	› Time to React@PCR
16:03	› Anatomical challenges for percutaneous mitral valve replacement <i>C. Ruiz</i>
16:08	› Time to React@PCR
16:13	› Session evaluation and key learnings <i>M. Mack</i>

<b>15:30 - 16:15</b>	<b>TAVI complications 2</b>
INTERACTIVE CASE CORNER	
Cases	
	<i>Session comprising selected PCR London Valves 2016 clinical case submissions</i>
	<b>Facilitators: D. Himbert, M.K.Y. Lee</b>
15:30	› Lond16C-ICC054 - Distal left anterior descending artery occlusion and ostial left main stenosis during transapical TAVI <i>U. Kaneko</i>
15:37	› Lond16C-ICC067 - Never give up in TAVI <i>L. Biasco</i>
15:44	› Lond16C-ICC072 - Hypo-attenuated leaflet thickening combined with right coronary occlusion three years after implantation of self-expandable valve <i>Y.B. Liao</i>
15:52	› Lond16C-ICC079 - TAVI complicated with subannular rupture and pseudoaneurysm fistulized to right atrium <i>V. Ruiz-Quevedo</i>
16:00	› Lond16C-ICC082 - Hypo-attenuated mass of bioprosthetic aortic valve one week after transcatheter aortic valve replacement in a bicuspid aortic stenosis patient <i>X. Wei</i>
16:08	› Lond16C-ICC084 - Self-limiting intrannular rupture following balloon expandable TAVI implantation <i>L. Paraggio (Pending approval)</i>

<b>15:30 - 16:15</b>	<b>Tricuspid</b>
ROOM 5	
Cases	
	<i>Session comprising selected PCR London Valves 2016 clinical case submissions</i>
	<b>Facilitator: U. Schäfer</b>
15:30	› Lond16C-ICC012 - MitraTrick MitraClip in tricuspid position: rationale and bench test <i>P. Denti</i>
15:39	› Lond16C-ICC098 - A tale of three valves <i>E. Karacop</i>
15:48	› Lond16C-ICC048 - Percutaneous balloon valvuloplasty for bioprosthetic tricuspid valve stenosis: two case reports <i>G. Hiasa</i>
15:57	› Lond16C-ICC076 - Transcatheter treatment of primary tricuspid regurgitation using the MitraClip system <i>D. Braun</i>
16:06	› Lond16C-ICC041 - Transcatheter tricuspid valve repair for functional tricuspid regurgitation <i>R. Hahn</i>


- 16:00 -

**16:30 - 17:15**  **LIVE demonstration from Clinique Pasteur - Toulouse, France**  
MAIN ARENA



**Chairpersons:** T. Lefèvre, C.K. Naber  
**Panellists:** D. Blackman, F. Hellig, R. Kornowski, P. MacCarthy, L. Sondergaard, C. Young


- 16:30 > Overview of the tools to be used during the LIVE demonstration  
*R. Kornowski*
- 16:35 **LIVE demonstration from Clinique Pasteur - Toulouse, France**
- 17:05 > Time to React@PCR

**16:30 - 17:30**  **Stroke and its prevention in the TAVI patient**  
ROOM 2  
Plenary

**Chairpersons:** A. Baumbach, S. Windecker  
**Panellists:** J.J. Bax, Ö. Göktekin (Pending approval), J.J. Popma, D. Walters

**Attend this session if you want:**

- > To understand the mechanisms of stroke during and after TAVI
- > To learn how to select the best procedural strategy for patients at high stroke risk
- > To learn more about medical treatment strategies to minimise stroke risk
- 16:30 > Session objectives  
*A. Baumbach*
- 16:34 > Cerebrovascular complications after valve intervention: incidence and new standardised definitions  
*A. Lansky*
- 16:41 > Time to React@PCR
- 16:47 > How do we identify stroke risk during and after TAVI?  
*A. Linke*
- 16:54 > Time to React@PCR
- 17:00 > Preventing periprocedural stroke using cerebral protection: which patient and which device?  
*H. Eggebrecht*
- 17:07 > Time to React@PCR
- 17:13 > Preventing post-procedural stroke using medical therapy: which patient and which regime?  
*J.P. Collet*
- 17:20 > Time to React@PCR
- 17:26 > Session evaluation and key learnings  
*S. Windecker*

**16:30 - 17:30**  **Advances in percutaneous mitral valve treatment**  
ROOM 3  
Plenary

**Chairpersons:** V. Bapat, C. Tamburino  
**Panellists:** P. Boekstegers, V. Delgado, M.B. Leon, T. Modine

**Attend this session if you want:**

- > To fully understand which patients need alternatives to edge-to-edge percutaneous repair
- > To appreciate the potential indications and limitations of percutaneous mitral valve annuloplasty and replacement
- > To know more about current imaging tools for percutaneous mitral valve annuloplasty and replacement
- 16:30 > Session objectives  
*V. Bapat*
- 16:34 > Unmet need for surgical and percutaneous treatment of mitral regurgitation  
*A. Vahanian*
- 16:41 > Time to React@PCR
- 16:47 > Pre- and periprocedural imaging to enable percutaneous mitral annuloplasty and replacement  
*S. Von Bardeleben*
- 16:54 > Time to React@PCR
- 17:00 > Transcatheter mitral annuloplasty - lessons we have learnt  
*H. Sievert*
- 17:07 > Time to React@PCR
- 17:13 > Transcatheter mitral valve replacement: which patients are suitable?  
*I. Meredith*
- 17:20 > Time to React@PCR
- 17:26 > Session evaluation and key learnings  
*C. Tamburino*

**16:30 - 17:30** ■ **TAVI: outcomes with new and established devices**

ROOM 4

Abstracts

*Session comprising selected PCR London Valves 2016 abstract submissions*

**Chairpersons: F. Castriota, M. Ng**  
**Panellists: S. Saito, G. Yucel**

- 16:30 > Lond16A-OP24 - Two-year outcomes with a fully repositionable and retrievable percutaneous aortic valve in 250 high surgical risk patients: results from the REPRISE II trial extended cohort  
*I. Meredith*
- 16:36 > Discussion and audience interaction
- 16:40 > Lond16I-OP02 - New modular aortic valve prosthesis  
*G. Melnick*
- 16:46 > Discussion and audience interaction
- 16:50 > Lond16I-OP04 - Safety and effectiveness of a novel transfemoral, supra-annular, early functional, retrievable transcatheter aortic valve system: primary results of the Nautilus multicentric study  
*P. Lemos*
- 16:56 > Discussion and audience interaction
- 17:00 > Lond16A-OP40 - One-year outcome of a multicentre clinical study evaluating a novel self-expanding and resheathable transcatheter aortic valve system  
*T. Walther*
- 17:06 > Discussion and audience interaction
- 17:10 > Lond16A-OP33 - First report of one-year outcomes in patients treated with a fully repositionable and retrievable aortic valve in routine clinical practice (RESPOND post-market registry)  
*N. Van Mieghem*
- 17:16 > Discussion and audience interaction
- 17:20 > Novel device: a unique self-expanding TAVI experience  
*U. Schäfer*
- 17:26 > Discussion and audience interaction

**16:30 - 17:30** ■ **TAVI complications 3**

INTERACTIVE CASE CORNER

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators: J. Hon, T. Schmitz**

Cases

- 16:30 > Lond16C-ICC086 - Ventricular dislocation of the low implanted transcatheter aortic valve in the patient with porcelain aorta and a narrow sino-tubular junction  
*J. Bulum*
- 16:38 > Lond16C-ICC100 - Transapical transcatheter closure of the left ventricular pseudoaneurysm after aortic valve replacement  
*J. Ito*
- 16:46 > Lond16C-ICC091 - Rapid solution for coronary obstruction during CoreValve implant - balloon extraction  
*T. Al-Badawi*
- 16:54 > Lond16C-ICC099 - TAVI: life threatening complication and out-of-the-box solution  
*N. Chouhan*
- 17:02 > Lond16C-ICC087 - Ascending aorta dissection after right coronary artery PCI and unsuccessful TAVI  
*M. Bunc*
- 17:09 > Lond16C-ICC104 - Complication on large annulus TAVI  
*Q. Labarre*
- 17:16 > Lond16C-ICC106 - A case where you wish to have a retrievable valve  
*S. Fournier*
- 17:23 > Lond16C-ICC107 - Valve-in-valve procedure in a patient with delayed transcatheter heart valve migration  
*J. Valle Raleigh*

<p><b>16:30 - 17:30</b> ROOM 5 Focus Nurses and Allied Professionals Plenary</p>	<p><b>The role of nurses and allied health professionals in the management of procedural complications</b></p> <p><i>Chairpersons: J. Byrne, K. Wilson</i> <i>Panellists: M. De Ronde, N. Delahunty (Pending approval), P. Ghandour</i></p> <p><b>Attend this session if you want:</b></p> <ul style="list-style-type: none"> <li>&gt; To understand how nurses and allied health professionals can make a difference when procedural complications arise</li> <li>&gt; To improve your knowledge of how to treat common complications during TAVI</li> <li>&gt; To improve team communication before, during and after procedural complications</li> </ul> <p>16:30 &gt; Session objectives <i>K. Wilson</i></p> <p>16:34 &gt; Case 1 (Vascular) <i>N. Delahunty (Pending approval)</i></p> <p>16:40 &gt; Time to React@PCR</p> <p>16:45 &gt; Case 2 (Aortic) <i>M. De Ronde</i></p> <p>16:53 &gt; Time to React@PCR</p> <p>17:00 &gt; Case 3 (Coronary) <i>P. Ghandour</i></p> <p>17:06 &gt; Time to React@PCR</p> <p>17:13 &gt; How do we learn when complications arise? Human factors and the importance of communication <i>M. Bowers</i></p> <p>17:20 &gt; Time to React@PCR</p> <p>17:26 &gt; Session evaluation and key learnings <i>J. Byrne</i></p>
--	--

- 17:00 -

<p><b>17:15 - 18:00</b> MAIN ARENA</p>	<p><b>LIVE demonstration from St. Thomas' Hospital - London, United Kingdom</b></p> <p><i>Chairpersons: T. Lefèvre, C.K. Naber</i> <i>Panellists: D. Blackman, F. Hellig, R. Kornowski, P. MacCarthy, L. Sondergaard, C. Young</i> <i>Operators: J. Hancock, B. Prendergast, S. Redwood</i></p> <p>17:15 &gt; Overview of the tools to be used during the LIVE demonstration <i>L. Sondergaard (Pending approval)</i></p> <p>17:20 <b>LIVE demonstration from St. Thomas' Hospital - London, United Kingdom</b></p> <p>17:50 &gt; Time to React@PCR</p>
--	---



<p><b>17:30 - 18:30</b> ROOM 4 Cases</p>	<p><b>International Forum 3: Spain-Mexico share their most educational cases</b></p> <p><i>Session comprising selected PCR London Valves 2016 clinical case submissions</i></p> <p>17:30 &gt; Lond16C-OP005 - TAVI in depressed ventricular function with low flow, low gradient aortic stenosis assisted with femoro-femoral cardiopulmonary bypass <i>J. Quintanilla</i></p> <p>17:38 &gt; Discussion and audience interaction</p> <p>17:45 &gt; Lond16C-OP049 - The role of the snare in a difficult TAVI <i>V. Ruiz-Quevedo</i></p> <p>17:53 &gt; Discussion and audience interaction</p> <p>18:00 &gt; Lond16C-OP144 - Transseptal mitral valve-in-valve implantation. Dealing with technical issues and complications <i>M. Alcantara</i></p> <p>18:08 &gt; Discussion and audience interaction</p> <p>18:15 &gt; Lond16C-OP065 - Three cases of early valve thrombosis after TAVI with Lotus valve <i>R.A. Hernandez</i></p> <p>18:23 &gt; Discussion and audience interaction</p>
--	---

**17:35 - 18:35** ■ **Understanding heart valve anatomy using multimodality imaging**  
ROOM 2  
Plenary

**Chairpersons:** *A. Baumbach, J.J. Bax*  
**Panellists:** *E. Brochet, R. Hahn, K. Hayashida, S. Von Bardeleben*

**Attend this session if you want:**

- > To understand heart valve anatomy across the spectrum of imaging modalities
- > To learn about the fluoroscopic anatomy of heart valves for transcatheter valve interventions
- > To appreciate the next steps in creating a new generation of interventional imaging specialists

- 17:35 > Session objectives  
*J.J. Bax*
- 17:38 > Heart valve anatomy: perspectives from the 3-chamber, 2-chamber and short-axis views  
*N. Piazza*
- 17:45 > Time to React@PCR
- 17:50 > Fluoroscopic heart valve anatomy - insights from CT and the link to echocardiography  
*D. Mylotte*
- 17:57 > Time to React@PCR
- 18:02 > Clinical case presentation - when multimodality imaging told the whole story  
*J. Byrne*
- 18:09 > Time to React@PCR
- 18:14 > How do we bring the specialities of intervention and imaging even closer? Perspectives from intervention  
*N. Van Mieghem*
- 18:20 > How do we bring the specialities of intervention and imaging even closer? Perspectives from imaging  
*V. Delgado*
- 18:26 > Time to React@PCR
- 18:31 > Session evaluation and key learnings  
*A. Baumbach*

- 08:00 -

**08:00 - 08:45**  
**MAIN ARENA**  
 Plenary

**Expanding TAVI to lower risk patients with bicuspid valve disease: optimising outcomes through imaging**

*Chairpersons: J.J. Bax, J. Webb*  
*Panellists: M. Chen, N. Dumonteil, K. Hayashida, A. Linke, P. Pibarot, J.J. Popma*

**Attend this session if you want:**

- > To fully understand the importance of bicuspid aortic valve pathology on clinical decision-making and TAVI outcomes
- > To know how to select an appropriate TAVI device for patients with bicuspid aortic valve disease
- > To learn tips and tricks to achieve optimal deployment depth in TAVI for bicuspid aortic valve disease

08:00 > Session objectives  
*J. Webb*

08:04 > Bicuspid aortic valve disease and associated aortopathy - a new challenge for interventional cardiologists  
*E. Brochet*

08:10 > Time to React@PCR

08:16 > Imaging to determine the correct TAVI device for bicuspid aortic valve disease: the concept of supra-annular sizing  
*N. Piazza*

08:22 > Time to React@PCR

08:28 > Imaging to guide optimal device deployment in bicuspid aortic valve disease: fluoroscopy, echocardiography, or both?  
*N. Dumonteil*

08:34 > Time to React@PCR

08:40 > Session evaluation and key learnings  
*J.J. Bax*

**08:00 - 09:25**  
**ROOM 2**  
 Plenary

**Valve-in-valve intervention: state of the art and future perspectives**

*Chairpersons: P. MacCarthy, S. Redwood*  
*Panellists: M. Gilard, R. Kornowski, M. Mack, H. Sievert*

**Attend this session if you want:**

- > To fully understand the current and future scope of percutaneous valve-in-valve intervention
- > To identify the key imaging requirements for patient evaluation and device selection
- > To learn key practical factors in achieving successful outcomes in percutaneous valve-in-valve and valve-in-ring procedures

08:00 > Session objectives  
*P. MacCarthy*

08:03 > Where are we up to? Current status and registry data  
*D. Dvir*

08:11 > Time to React@PCR

08:19 > Imaging is key to successful outcomes - defining the mechanism of valve failure and guiding device selection  
*R. Hahn*

08:27 > Time to React@PCR

08:35 > Aortic valve-in-valve - a user's guide  
*F. Castriota*

08:43 > Time to React@PCR

08:51 > Mitral and tricuspid valve-in-valve and valve-in-ring - a user's guide  
*V. Bapat*

08:59 > Time to React@PCR

09:07 > Where are we going? Future clinical strategies and technical innovations  
*M. Abdel-Wahab*

09:15 > Time to React@PCR

09:23 > Session evaluation and key learnings  
*S. Redwood*

**08:00 - 09:00**  
**ROOM 3**

**Learning transfemoral access and closure for TAVI - technical aspects and complication management**



*Facilitators: T. Lefèvre, N. Van Mieghem*  
*Media Driver: D. Natarajan*

**Attend this session if you want:**

- > To learn the essential techniques for successful transfemoral access and closure
- > To appreciate the circumstances when transfemoral access is best avoided
- > To fully understand how to prevent and manage vascular complications of TAVI



**08:00 - 09:25** **TAVI complications and their prevention**

ROOM 4

Abstracts

*Session comprising selected PCR London Valves 2016 abstract submissions*

**Chairpersons: J. Byrne, A. Lansky**  
**Panellists: D. Himbert, H.L. Kao**

- 08:00 > Lond16A-OP71 - Subclinical leaflet thickening in a novel mechanical expanded TAVI device  
*R. Gooley*
- 08:06 > Discussion and audience interaction
- 08:10 > Lond16A-OP11 - Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVI  
*R. Yanagisawa*
- 08:16 > Discussion and audience interaction
- 08:20 > Lond16A-OP44 - Safety and efficacy of the cerebral embolic protection device during TAVI: results from a single-centre experience  
*M. Dallago*
- 08:26 > Discussion and audience interaction
- 08:30 > Lond16A-OP17 - The effect of transcatheter aortic valve replacement on cognition - a prospective pilot study  
*M. Abawi*
- 08:36 > Discussion and audience interaction
- 08:41 > Lond16A-OP55 - Evaluation of the incidence, timing, and potential recovery rates of complete atrioventricular block after TAVI: a Japanese multicentre registry study  
*A. Kagase*
- 08:47 > Discussion and audience interaction
- 08:52 > Lond16A-OP20 - Impact of implantation depth for pacemaker need after implantation of a fully repositionable and retrievable aortic valve - insights from the respond post-market study  
*L. Van Gils*
- 08:58 > Discussion and audience interaction
- 09:03 > Lond16A-OP66 - Role of implantation depth on pacemaker rate and paravalvular leakage after balloon expandable TAVI  
*S. Fateh-Moghadam (Pending approval)*
- 09:09 > Discussion and audience interaction
- 09:14 > Lond16A-OP31 - Assessment of aortic regurgitation by contrast densitometry angiography in the setting of TAVI; echocardiographic correlates  
*M. Abdelghani*
- 09:20 > Discussion and audience interaction

**08:00 - 09:25** **TAVI: vascular access, coronary disease**

INTERACTIVE CASE CORNER

Cases

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators: A.S. Petronio, T. Walther**

- 08:00 > Lond16C-ICC030 - Same setting right and then left 18F femoral access for TAVI. Bailout access site manoeuvres  
*G. Latsios*
- 08:08 > Lond16C-ICC095 - Difficult transfemoral access in TAVI: snare could be an option  
*E. Karacop*
- 08:16 > Lond16C-ICC108 - Bending the rules in transfemoral TAVI: overcoming severe iliac tortuosity  
*J. Michel*
- 08:24 > Lond16C-ICC109 - Steps to manage potential "suicide left ventricle" in TAVI patient  
*R. Wolff*
- 08:32 > Lond16C-ICC110 - Transfemoral complex TAVI procedure in patient with bicuspid aortic valve stenosis and previous surgical treatment for abdominal aortic aneurism  
*L. Salemme*
- 08:40 > Lond16C-ICC123 - Difficult implantation of second Evolut valve through the first one  
*P. Kubler*
- 08:48 > Lond16C-ICC165 - Severely tortous anatomy in patient treated with transfemoral TAVI  
*B. Rymuza (Pending approval)*
- 08:56 > Lond16C-ICC166 - When deep implantation is not an option  
*G. Katsimagklis*
- 09:04 > Lond16C-ICC093 - A case of minimum contrast TAVI screening in end-stage renal dysfunction  
*T. Sakamoto*
- 09:11 > Lond16C-ICC113 - TAVI with PCI of the left main  
*J.H. Kim*
- 09:18 > Lond16C-ICC155 - Transaortic TAVI and LIMA-left anterior descending under extracorporeal membrane oxygenation support in a no option patient  
*N. Bonaros*

**08:00 - 09:25** ■ **Mitral complication and hole closure after valve interventions**

ROOM 5

Cases

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators: C. Grasso, F. Nietlispach**

- 08:00 > Lond16C-ICC092 - Occult mitral valve damage after percutaneous mitral valve edge-to-edge repair  
*Z. Rahhab*
- 08:09 > Lond16C-ICC118 - Valve-in-ring mitral. Post-operative valve thrombosis  
*G. Dahle*
- 08:18 > Lond16C-ICC120 - Sudden thrombosis after transapical valve-in-ring procedure in mitral position  
*Liewald*
- 08:27 > Lond16C-ICC129 - Two clips, not enough to stabilise a partial clip detachment  
*J. Morales Portano*
- 08:36 > Lond16C-ICC014 - Successful percutaneous closure of a large prosthetic tricuspid valve paravalvular leak with two VSD occluders in patient with previous metallic mitral valve ring  
*R. Anantharaman*
- 08:45 > Lond16C-ICC017 - Double approach mitral paravalvular leak closure  
*P. Dardas*
- 08:55 > Lond16C-ICC033 - Percutaneous treatment of severe transvalvular and paravalvular regurgitation in a failing surgical aortic valve prosthesis due to recurrent endocarditis  
*R.K. Binder*
- 09:05 > Lond16C-ICC073 - Plugging paravalvular leak immediately after TAVI with self-expandable valve in a patient with stenotic bicuspid anatomy  
*Y. Feng*
- 09:15 > Lond16C-ICC130 - A case of transeptal and transapical access for transcatheter closure of mitral prothetic paravalvular leak  
*R. Sádaba*

**08:45 - 09:30** ■ **LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**

MAIN ARENA



**Chairpersons: J.J. Bax, J. Webb**  
**Panellists: M. Chen, N. Dumonteil, K. Hayashida, A. Linke, P. Pibarot, J.J. Popma**

- 08:45 > Overview of the tools to be used during the LIVE demonstration  
*A. Linke (Pending approval)*
- 08:50 **LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**
- 09:20 > Time to React@PCR

**- 09:00 -**

**09:30 - 10:30** ■ **Secondary mitral regurgitation: percutaneous strategies to improve outcomes**

ROOM 2

Plenary

**Chairpersons: T. Feldman, H. Ince**  
**Panellists: P. Boekstegers, F. Hellig, F. Praz, U. Schäfer**

**Attend this session if you want:**

- > To understand when and how edge-to-edge repair fails in the treatment of secondary mitral regurgitation
  - > To identify predictors of failure and propose strategies to improve outcomes after edge-to-edge repair of secondary mitral valve regurgitation
  - > To advance hypotheses for future patient selection criteria for percutaneous treatment options in patients with secondary mitral regurgitation
- 09:30 > Session objectives  
*H. Ince*
  - 09:34 > Secondary mitral regurgitation - limitations of current medical and device therapy and the need for percutaneous treatment  
*A. Vahanian*
  - 09:41 > Time to React@PCR
  - 09:47 > Percutaneous edge-to-edge repair in secondary mitral regurgitation - current outcomes and predictors of failure  
*C. Grasso*
  - 09:54 > Time to React@PCR
  - 10:00 > Alternative percutaneous approaches for secondary mitral regurgitation  
*V. Bapat*
  - 10:07 > Time to React@PCR
  - 10:13 > A further challenge for percutaneous treatment: secondary mitral regurgitation as a result of severe aortic stenosis  
*U. Schäfer*
  - 10:20 > Time to React@PCR
  - 10:26 > Session evaluation and key learnings  
*T. Feldman*

**09:30 - 10:30**  
**ROOM 4**  
**Cases**

**International Forum 4: PCR-CIT  
 China Chengdu Valves and PCR  
 Tokyo Valves share their most  
 educational cases**

**Chairpersons: M. Chen, P. MacCarthy**  
**Panellist: C.K. Naber (Pending approval)**

- 09:30 > PCR London Valves welcomes PCR-CIT  
China Chengdu Valves and PCR Tokyo  
Valves  
*P. MacCarthy*
- 09:33 > Case 1: TAVI in a bicuspid valve  
*M.K.Y. Lee*
- 09:39 > How would I treat?  
*S. Saito*
- 09:43 > Discussion and audience interaction
- 09:47 > How did I treat?  
*M.K.Y. Lee*
- 09:51 > Case 2: valve-in-valve TAVI
- 09:57 > How would I treat?  
*H.L. Kao (Pending approval)*
- 10:01 > Discussion and audience interaction
- 10:05 > How did I treat?  
*K. Hayashida*
- 10:09 > Case 3: TAVI complication  
*X. Wei (Pending approval)*
- 10:15 > How would I treat?  
*T. Sakamoto (Pending approval)*
- 10:19 > Discussion and audience interaction
- 10:23 > How did I treat?  
*X. Wei (Pending approval)*
- 10:27 > Session evaluation and key learnings  
*M. Chen*

**09:30 - 10:30**

**INTERACTIVE  
 CASE CORNER**

*Session comprising selected PCR London Valves  
 2016 clinical case submissions*

**Facilitators: D. Blackman, N. Dumonteil**

**Cases**

- 09:30 > Lond16C-ICC112 - TAVI in TAVI for  
paravalvular regurgitation after TAVI  
*D.S. Sim*
- 09:37 > Lond16C-ICC114 - Left ventricular outflow  
tract-migrated transcatheter heart valve  
*L. Salido-Tahoces*
- 09:44 > Lond16C-ICC116 - Spontaneous coronary  
intramural dissection with haematoma  
post-replacement of aortic valve  
*F.C. Liao (Pending approval)*
- 09:51 > Lond16C-ICC124 - TAVI unusual  
complication  
*J. Sandoval*
- 09:58 > Lond16C-ICC127 - Late migration (28  
months after implantation) of  
transcatheter mitral valve in ring requiring  
surgical reoperation  
*M. Yates*
- 10:06 > Lond16C-ICC132 - Creating stability: one  
method of treating an embolised TAVI  
device  
*R. Gooley*
- 10:14 > Lond16C-ICC136 - Partial deployment of a  
balloon expandable valve due to delivery  
system failure: expect the unexpected  
*M. Chrissoheris*
- 10:22 > Lond16C-ICC139 - Late shifting  
transcatheter self-expandable valve down  
to the left ventricle treated with re-TAVI  
procedure  
*D. Stolyarov*

**09:30 - 10:30 TAVI in bicuspid valves**

ROOM 5

*Session comprising selected PCR London Valves 2016 clinical case submissions*

Cases

**Facilitator: R. Kornowski**

- 09:30 > Lond16C-ICC036 - Full transcatheter treatment of bicuspid aortic valve stenosis and aortic coarctation in a 76-year-old female  
*F. van der Kley*
- 09:37 > Lond16C-ICC061 - Transfemoral TAVI in a complex bicuspid anatomy  
*J. Molina-Martin de Nicolas*
- 09:44 > Lond16C-ICC083 - Extremely high deployment of an undersized TAVI prosthesis to treat heavily calcified bicuspid aortic valve  
*L. Paraggio (Pending approval)*
- 09:51 > Lond16C-ICC085 - Transfemoral TAVI in an intermediate risk patient with bicuspid aortic valve and high embolic risk  
*P. Gatto*
- 09:58 > Lond16C-ICC122 - TAVI treatment for a patient with bicuspid aortic valve and mild asymmetrical calcification  
*Y.N. Xu*
- 10:06 > Lond16C-ICC149 - Five cases of bicuspid aortic stenosis with transcatheter aortic valve replacement  
*R. Muratalla*
- 10:14 > Lond16C-ICC167 - Successful TAVI in bicuspid anatomy with a new self-expandable device  
*Z.G. Zhao*
- 10:22 > Lond16C-ICC023 - Lotus TAVI implantation in a bicuspid aortic valve: when position matters...  
*R. Nerla*

**09:35 - 10:30 The Great Valve Debate: is TAVI the new gold standard in the treatment of patients with aortic stenosis?**

MAIN ARENA

Plenary

*Supported by an educational grant from Edwards Lifesciences*

**Chairpersons: J.J. Bax, M. Haude**  
**Panellists: N. Moat, T. Modine, A.S. Petronio**

**- 11:00 -**

**11:00 - 11:45 Trials and registries 2016: what do they mean?**

MAIN ARENA

Plenary

**Chairpersons: M. Gilard, O. Wendler**  
**Panellists: A. Baumbach, P. Chiam, C. Hamm, A. Lansky, R. Makkar, N. Moat**  
**React@PCR Moderator: S. Cannata (Pending approval)**

**Attend this session if you want:**

- > To hear a summary of the latest data concerning percutaneous valve intervention
- > To appreciate the limitations and shortcomings of the available evidence base
- > To fully understand how to incorporate the findings of randomised controlled trials and large scale registries into your everyday practice

11:00

- > Session objectives  
*M. Gilard*

11:03

**The TAVI randomised controlled trials**

- > The data and their limitations  
*L. Sondergaard*

11:10

- > Messages for everyday practice  
*S. Redwood*

11:16

- > Time to React@PCR

**The mitral registries**

11:23

- > The data and their limitations  
*M. Mack*

11:30

- > Messages for everyday practice  
*H. Ince*

11:36

- > Time to React@PCR

11:43

- > Session evaluation and key learnings  
*O. Wendler*

**11:00 - 12:30** ■ **RAPID FIRE: innovations in**

ROOM 2

Plenary

**percutaneous tricuspid intervention**

**Chairpersons:** *R. Hahn (Pending approval), M. Haude*  
**Panellists:** *J. Hancock (Pending approval), D. Mylotte, C. Ruiz, H. Treede*  
**React@PCR Moderator:** *H. McConkey (Pending approval)*

**Attend this session if you want:**

- › To fully understand the anatomical and technical challenges associated with percutaneous tricuspid intervention
- › To hear the latest outcome data concerning cutting edge technologies with first in man experience
- › To identify the limitations of currently available devices

- 11:00 › Session objectives  
*R. Hahn (Pending approval)*
- 11:04 › What are the anatomical and technical challenges in percutaneous tricuspid intervention?  
*F. Maisano*
- 11:11 › Lond16I-OP11 - Navigating to the tricuspid valve for transfemoral interventional tricuspid valve repair  
*M. Nabauer*
- 11:19 › Lond16I-OP03 - Tricuspid repair with the Trialign system  
*J. Schofer*
- 11:27 › Lond16LBT-OP04 - Early feasibility of a percutaneous tricuspid valve annuloplasty system for symptomatic chronic functional tricuspid regurgitation: 30-day results of the SCOUT trial  
*R. Hahn*
- 12:19 › What does the future hold?  
*A. Latib*
- 12:26 › Session evaluation and key learnings  
*M. Haude*

**11:00 - 12:30** ■ **Learning TAVI for failing aortic bioprostheses and bicuspid valves**

ROOM 3



**Facilitators:** *M.K.Y. Lee, H. Moellmann*  
**Media Driver:** *D. Natarajan*  
**Expert Panellist:** *K. Hayashida*

**Attend this session if you want:**

- › To learn how to plan TAVI for a failing aortic bioprosthesis or bicuspid valve
- › To appreciate the key technical aspects of the TAVI procedure in this clinical setting
- › To fully understand how to predict and prevent complications of TAVI for a failing aortic bioprosthesis or bicuspid valves

**11:00 - 12:30** ■ **TAVI unusual cases**

INTERACTIVE CASE CORNER

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Facilitators:** *J. Hon, J.J. Popma*

Cases

- 11:00 › Lond16C-ICC053 - Subaortic compressive pseudoaneurysm treated by transcatheter self-expanding CoreValve prosthesis  
*G. Sardella*
- 11:08 › Lond16C-ICC019 - Mechanical thrombectomy of embolised native aortic valve during TAVI  
*J. Coughlan (Pending approval)*
- 11:16 › Lond16C-ICC043 - Mobile mass at aortic valve in patient with severe aortic stenosis undergoing TAVI  
*S. Sasaki*
- 11:24 › Lond16C-ICC018 - Aortic regurgitation due to mobile chronic valve vegetation treated with TAVI - first-human case  
*A.B. Gopalamurugan*
- 11:32 › Lond16C-ICC071 - TAVI in a heart failure patient with a left ventricular assist device and severe aortic regurgitation  
*F. van der Kley*
- 11:40 › Lond16C-ICC126 - TAVI transcaval with lotus valve  
*J. Sandoval*
- 11:48 › Lond16C-ICC131 - TAVI for failed aortic homograft with severe regurgitation - superior treatment to redo surgery?  
*T. Al-Badawi*
- 11:56 › Lond16C-ICC134 - Severe aortic stenosis and acute type A proximal aortic dissection: a self-expandable valve to treat both  
*M. Chrissoheris*
- 12:04 › Lond16C-ICC150 - Complete percutaneous management of cardiac diseases: three devices for one heart  
*R. Muratalla*
- 12:12 › Lond16C-ICC154 - TAVI in a heart transplanted patient affected by acromegaly  
*E. Raviola*
- 12:21 › Lond16C-ICC168 - Compassionate use of a self-expanding aortic valve bioprosthesis for severe aortic regurgitation in cardiogenic shock without aortic valve stenosis or annular calcification  
*M. Patel*

**11:00 - 12:30 Percutaneous mitral therapies**

ROOM 5

Session comprising selected PCR London Valves 2016 clinical case submissions

Cases

**Facilitators: K.H. Kuck, C. Tamburino**

- 11:00 > Lond16C-ICC004 - Wire-assisted Inoue balloon crossing extremely narrow mitral orifice-rescue method when all the techniques failed  
*C.W. Lee*
- 11:07 > Lond16C-ICC063 - Saved by a thread!  
*M. Settergren*
- 11:14 > Lond16C-ICC090 - First experience with a transcatheter mitral valve with apical tether  
*G. Dahle*
- 11:21 > Lond16C-ICC111 - Implantation of a mechanically expanding transcatheter valve for severe mitral stenosis  
*N. Uren (Pending approval)*
- 11:28 > Lond16C-ICC146 - Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy  
*M. Taramasso*
- 11:35 > Lond16C-ICC042 - Double clips, double the trouble!  
*G. Tang*
- 11:42 > Lond16C-ICC142 - Transcatheter mitral valve-in-ring for prosthetic valve dysfunction  
*R. Tanner*
- 11:49 > Lond16C-ICC056 - Successful percutaneous edge-to-edge treatment for severe rheumatic mitral regurgitation  
*K.K. Yeo*
- 11:56 > Lond16C-ICC066 - Recurrent intraclips mitral regurgitation : an unconventional treatment approach  
*L. Biasco (Pending approval)*
- 12:03 > Lond16C-ICC133 - MitraClip transcatheter mitral valve repair: an alternative treatment for double orifice mitral valve with flail leaflet  
*Z. Wang*
- 12:10 > Lond16C-ICC070 - Transseptal mitral valve-in-valve  
*N. Uren (Pending approval)*
- 12:17 > Lond16C-ICC115 - Transapical mitral valve in ring implantation after mitral valve repair failure  
*D. Jagielak*
- 12:24 > Lond16C-ICC055 - Emergency cardiac surgery for irreversible MitraClip delivery system entrapment  
*G. Sardella*

**11:45 - 12:30 LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**

MAIN ARENA



**Chairpersons: M. Gilard, O. Wendler**  
**Panellists: A. Baumbach, P. Chiam, C. Hamm, A. Lansky, R. Makkar, N. Moat**  
**React@PCR Moderator: S. Cannata (Pending approval)**

- 11:45 > Overview of the tools to be used during the LIVE demonstration  
*N. Moat (Pending approval)*
- 11:50 **LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**
- 12:20 > Time to React@PCR

- 09:00 -

09:00 - 10:30  
ROOM 3



**Learning how to make your TAVI programme more efficient and cost effective**

**Facilitators:** C. Tamburino, D. Tchétché  
**Media Driver:** S. Cannata

**Attend this session if you want:**

- > To learn how your TAVI service can be more streamlined and cost-effective
- > To understand when conscious sedation and general anaesthesia are most appropriate for TAVI
- > To understand the key principles of safe early discharge after TAVI

- 13:00 -

13:00 - 14:40  
MAIN ARENA

Tools and Techniques



**Cardioband: clinical reality for mitral and tricuspid valve repair**

*Sponsored by Valtech Cardio*

**Chairpersons:** E. Grube, K.H. Kuck  
**Panellists:** A. Latib, F. Maisano, G. Nickenig, S. Von Bardeleben (Pending approval)  
**React@PCR Moderator:** S. Cannata (Pending approval)

**Attend this session if you want:**

- > To understand how to perform mitral repair in patients with functional mitral regurgitation
- > To learn more about case examples of the Cardioband procedures
- > To learn about the evolution of Cardioband for treating heart failure

- 13:00 > Session objectives  
*E. Grube*
- 13:05 > 24-month results and clinical studies update  
*K.H. Kuck*
- 13:15 > 100 patients: lessons learned  
*F. Maisano*
- 13:25 **Recorded case**
- 13:50 > Time to React@PCR
- 13:55 > Cardioband, synergetic with other treatments  
*A. Latib*
- 14:05 > Echo Guidance: following the anatomy and physiology  
*S. Von Bardeleben (Pending approval)*
- 14:15 > Time to React@PCR
- 14:20 > Tricuspid repair with Cardioband  
*G. Nickenig*
- 14:30 > Time to React@PCR
- 14:35 > Session evaluation and key learnings  
*E. Grube*

13:00 - 13:45

ROOM 2

Symposium



**Direct Flow Medical: driving excellent patient outcomes today and tomorrow**

*Sponsored by Direct Flow Medical*

**Chairpersons:** J.J. Popma, D. Tchétché  
**Panellists:** F. De Marco, S. Gafoor, M. Gilard

**Attend this session if you want:**

- > To deep dive into the latest data from Direct Flow Medical TAVI technology
- > To learn advanced Direct Flow Medical TAVI system implant techniques
- > To learn about the Direct Flow Medical mitral programme

- 13:00 > Session objectives  
*D. Tchétché*
- 13:03 > Aortic programme - a deep-dive into the clinical evidence  
*A. Latib (Pending approval)*
- 13:11 > Time to React@PCR
- 13:16 > Complete procedural control - reaching the goal of 'no aortic regurgitation'  
*S. Lim (Pending approval)*
- 13:24 > Time to React@PCR
- 13:29 > Mitral programme update  
*N. Moat*
- 13:37 > Time to React@PCR
- 13:42 > Session evaluation and key learnings  
*J.J. Popma*

13:00 - 14:40

ROOM 4

Tools and Techniques



**Tricuspid repair with the Trialign system**

*Sponsored by Mitralign*

**Chairperson:** M.B. Leon (Pending approval)

**Panellists:** R. Hahn (Pending approval), L. Labrousse, A. Latib (Pending approval), J. Schofer

**Attend this session if you want:**

- > To familiarise yourself with tricuspid repair techniques
- > To develop an understanding of tricuspid imaging
- > To understand a Trialign procedure

- 13:00 > Session objectives  
*M.B. Leon (Pending approval)*
- 13:05 > Surgical repair techniques  
*L. Labrousse*
- 13:13 > Discussion and audience interaction
- 13:18 > Trialign techniques  
*A. Latib (Pending approval)*
- 13:26 > Discussion and audience interaction
- 13:32 > Echocardiology tips and tricks  
*R. Hahn (Pending approval)*
- 13:40 > Discussion and audience interaction
- 13:45 **Recorded case from Hamburg University Cardiovascular Center - Hamburg, Germany**  
*J. Schofer*
- 14:30 > Discussion and audience interaction
- 14:35 > Session evaluation and key learnings  
*M.B. Leon (Pending approval)*

- 14:00 -

**14:45 - 15:30**  
MAIN ARENA

 **LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**

*Chairpersons: J. Fajadet, M. Haude (Pending approval)*  
*Panellists: R. Kornowski, N. Piazza, S. Redwood (Pending approval), C. Tamburino, D. Tchétché, O. Wendler*  
*React@PCR Moderator: H. McConkey (Pending approval)*

- 14:45 > Overview of the tools to be used during the LIVE demonstration  
*S. Redwood (Pending approval)*
- 14:50 **LIVE demonstration from Swiss Cardiovascular Centre, Bern University Hospital - Bern, Switzerland**
- 15:20 > Time to React@PCR

**14:45 - 15:45**  
ROOM 2  
Plenary

**Technical challenges in percutaneous mitral edge-to-edge repair - learning from difficult cases**

*Chairpersons: T. Feldman, G. Nickenig*  
*Panellists: H. Ince, F. Maisano, H. Treede, K.K. Yeo*

**Attend this session if you want:**

- > To be updated on the results of percutaneous edge-to-edge repair and the determinants of success / failure
- > To understand the technical difficulties which may be encountered during percutaneous edge-to-edge repair
- > To identify strategies to overcome difficult anatomy in percutaneous treatment of mitral regurgitation

- 14:45 > Session objectives  
*G. Nickenig*
- 14:50 > Case 1: clipping after failed percutaneous repair  
*C. Grasso*
- 14:55 > Time to React@PCR
- 15:00 > Case 2: clipping after failed surgical repair  
*P. Boekstegers*
- 15:05 > Time to React@PCR
- 15:10 > Case 3: Barlow disease  
*F. Maisano*
- 15:15 > Time to React@PCR
- 15:20 > Case 4: extreme tethering in secondary mitral regurgitation  
*M. Buch*
- 15:25 > Time to React@PCR
- 15:30 > Case 5: clipping in cardiogenic shock  
*K.H. Kuck*
- 15:35 > Time to React@PCR
- 15:40 > Session evaluation and key learnings  
*T. Feldman*

**14:45 - 15:45**  
ROOM 3  
Plenary

**Extending the indications for TAVI to patients with asymptomatic severe aortic stenosis**

*Chairpersons: M.B. Leon, P. Pibarot*  
*Panellists: E. Grube, K. Hayashida, F. Hellig, A. Linke*

**Attend this session if you want:**

- > To understand in more detail the natural history of aortic stenosis
- > To explore the potential of minimally invasive valve therapy in the asymptomatic patient
- > To understand how earlier intervention could improve long-term outcomes

- 14:45 > Session objectives  
*P. Pibarot*
- 14:50 > The continuum of aortic stenosis: when does the real risk begin?  
*P. MacCarthy (Pending approval)*
- 14:55 > Time to React@PCR
- 15:00 > Identifying the at-risk patient - symptoms, biomarkers, imaging  
*J.J. Bax*
- 15:05 > Time to React@PCR
- 15:10 > Early intervention versus watchful waiting in asymptomatic severe aortic stenosis - current data  
*H. Moellmann*
- 15:15 > Time to React@PCR
- 15:20 > Potential advantages of TAVI over surgical aortic valve replacement in asymptomatic patients  
*A. Cribier*
- 15:25 > Time to React@PCR
- 15:30 > What about moderate aortic stenosis and heart failure? Should we give TAVI the benefit of the doubt?  
*N. Van Mieghem*
- 15:35 > Time to React@PCR
- 15:40 > Session evaluation and key learnings  
*M.B. Leon*



**14:45 - 15:45** ■ **Graders choice: the top 5 cases of 2016**

ROOM 4

Cases

*Session comprising selected PCR London Valves 2016 clinical case submissions*

**Chairpersons: J. Byrne, B. Prendergast**  
**Panellists: N. Dumonteil, A. Latib, T. Lefèvre, C. Ruiz**

- 14:45 > Lond16C-OP045 - Transcatheter tricuspid clipping after mitral clipping using echo and fluoro guidance  
*G. Tang*
- 14:52 > Discussion and audience interaction
- 14:57 > Lond16C-OP050 - Emergency left main PCI with "chimney technique" to treat coronary artery occlusion after valve-in-valve TAVI  
*R. Nerla*
- 15:04 > Discussion and audience interaction
- 15:09 > Lond16C-OP089 - Kissing balloons in the aorta  
*S. Toggweiler*
- 15:16 > Discussion and audience interaction
- 15:21 > Lond16C-OP137 - Successful stent-retriever thrombectomy for acute cerebral embolisation after TAVI  
*M. Miura*
- 15:28 > Discussion and audience interaction
- 15:33 > Lond16C-OP147 - Persistent tricuspid regurgitation after percutaneous mitral repair: a complete transcatheter treatment  
*M. Taramasso*
- 15:40 > Discussion and audience interaction

**- 15:00 -**

**15:30 - 16:30**

MAIN ARENA

Plenary

■ **Complications of percutaneous valve intervention - nightmare scenarios and heroic escapes**

**Chairpersons: J. Fajadet, M. Haude**  
*(Pending approval)*  
**Panellists: R. Kornowski, N. Piazza, S. Redwood** *(Pending approval)*, **C. Tamburino, D. Tchétché, O. Wendler**  
**React@PCR Moderator: H. McConkey**  
*(Pending approval)*

**Attend this session if you want:**

- > To learn practical tips and tricks to prevent and manage complications of percutaneous valve interventions
- > To understand the importance of imaging in the detection and management of procedural complications
- > To appreciate that even high volume experts get it wrong (sometimes)

15:30

- > Session objectives  
*J. Fajadet*

15:33

- > Prevention and management of complications during percutaneous valve intervention - top tips  
*A. Colombo*

**My worst complication during a percutaneous aortic valve procedure**

15:42

- > Case 1 - The imager saves the day  
*J. Hancock* *(Pending approval)*

15:47

- > Case 2 - The interventionist saves the day  
*H. Eltchaninoff*

15:52

- > Time to React@PCR

**My worst complication during a percutaneous mitral valve procedure**

15:57

- > Case 3 - The imager saves the day  
*R. Hahn*

16:02

- > Case 4 - The interventionist saves the day  
*S. Von Bardeleben* *(Pending approval)*

16:07

- > Time to React@PCR

**My worst complication during a valve-in-valve procedure**

16:12

- > Case 5 - The imager saves the day  
*M. Monaghan*

16:17

- > Case 6 - The interventionist saves the day  
*D. Hildick-Smith*

16:22

- > Time to React@PCR

16:27

- > Session evaluation and key learnings  
*M. Haude* *(Pending approval)*

**- 16:00 -**

**16:30 - 16:45**

MAIN ARENA

Ceremony

■ **Highlights of the Course**

**Chairpersons: M. Haude, B. Prendergast**  
**Panellists: J. Fajadet, N. Piazza, S. Redwood, C. Tamburino, O. Wendler, W. Wijns**

16:30

- > Concluding remarks  
*B. Prendergast*

16:40

- > PCR London Valves 2017  
*M. Haude* *(Pending approval)*